Bachem with Slight Sales Growth in the First Half of 2024. Outlook Confirmed for Full Year
Bachem Group (SIX: BANB) reported a slight sales growth of 0.2% to CHF 240.3 million in the first half of 2024, with a 1.3% increase in local currencies. EBITDA rose by 5.6% to CHF 55.5 million, with a margin of 23.1%. The company expects mid- to high-single-digit percentage growth in local currencies for 2024, maintaining a stable EBITDA margin. Bachem aims for annual sales exceeding CHF 1 billion and an EBITDA margin over 30% by 2026.
Sales in the Commercial API category declined by 13.4%, while CMC Development saw an 18.7% increase. The company is expanding production capacities globally, with significant investments across all sites. Bachem has begun commissioning equipment in its largest production plant for peptides and oligonucleotides in Bubendorf and is planning a new manufacturing site in Eiken.
Il Gruppo Bachem (SIX: BANB) ha registrato una lieve crescita delle vendite dello 0,2%, raggiungendo i 240,3 milioni di CHF nella prima metà del 2024, con un incremento dell'1,3% nelle valute locali. EBITDA è aumentato del 5,6% a 55,5 milioni di CHF, con un margine del 23,1%. L'azienda si aspetta una crescita percentuale a singola cifra medio-alta nelle valute locali per il 2024, mantenendo un margine EBITDA stabile. Bachem punta a superare le vendite annuali di 1 miliardo di CHF e a ottenere un margine EBITDA superiore al 30% entro il 2026.
Le vendite nella categoria Commercial API sono diminuite del 13,4%, mentre lo sviluppo CMC ha visto un incremento del 18,7%. L'azienda sta espandendo le capacità di produzione a livello globale, con investimenti significativi in tutti i siti. Bachem ha iniziato la messa in servizio delle attrezzature nel suo più grande stabilimento di produzione per peptidi e oligonucleotidi a Bubendorf e sta pianificando un nuovo sito produttivo a Eiken.
El Grupo Bachem (SIX: BANB) reportó un ligero crecimiento en las ventas del 0,2%, alcanzando los 240,3 millones de CHF en la primera mitad de 2024, con un aumento del 1,3% en las monedas locales. EBITDA creció un 5,6% hasta 55,5 millones de CHF, con un margen del 23,1%. La empresa espera un crecimiento porcentual de dígito único medio a alto en monedas locales para 2024, manteniendo un margen EBITDA estable. Bachem tiene como objetivo superar las ventas anuales de 1 mil millones de CHF y un margen EBITDA superior al 30% para 2026.
Las ventas en la categoría Comercial API disminuyeron un 13,4%, mientras que el desarrollo CMC vio un incremento del 18,7%. La empresa está expandiendo sus capacidades de producción a nivel mundial, con inversiones significativas en todos los sitios. Bachem ha comenzado a comisionar equipos en su planta de producción más grande para péptidos y oligonucleótidos en Bubendorf, y está planeando un nuevo sitio de fabricación en Eiken.
바켐 그룹(Bachem Group, SIX: BANB)은 2024년 상반기에 2.4억 스위스 프랑(240.3 million CHF)의 매출을 기록하며 0.2%의 소폭 성장률을 보였습니다. 현지 통화 기준으로는 1.3% 증가했습니다. EBITDA는 5.6% 증가하여 5,550만 스위스 프랑(55.5 million CHF)에 도달하며 23.1%의 마진을 기록했습니다. 회사는 2024년 현지 통화 기준으로 중간에서 높은 단일 숫자 성장률을 기대하고 있으며, 안정적인 EBITDA 마진을 유지할 계획입니다. 바켐은 2026년까지 연간 매출 10억 스위스 프랑 이상 및 30% 이상의 EBITDA 마진을 목표로 하고 있습니다.
상업 API 부문 매출은 13.4% 감소한 반면, CMC 개발 부문은 18.7% 증가했습니다. 바켐은 전 세계적으로 생산 능력을 확장하고 있으며, 모든 사이트에서 상당한 투자를 진행하고 있습니다. 바켐은 부벤도르프(Bubendorf)에 있는 가장 큰 펩타이드 및 올리고뉴클레오타이드 생산 공장에서 장비를 가동하기 시작했으며, 아이켄(Eiken)에 새로운 제조 사이트를 계획하고 있습니다.
Le Groupe Bachem (SIX: BANB) a signalé une légère croissance de son chiffre d'affaires de 0,2%, atteignant 240,3 millions de CHF au premier semestre 2024, avec une augmentation de 1,3% dans les devises locales. EBITDA a augmenté de 5,6% pour atteindre 55,5 millions de CHF, avec une marge de 23,1%. L'entreprise prévoit une croissance à un chiffre, de type moyen à élevé dans les devises locales pour 2024, tout en maintenant une marge EBITDA stable. Bachem vise à dépasser 1 milliard de CHF de ventes annuelles et une marge EBITDA supérieure à 30% d'ici 2026.
Les ventes dans la catégorie Commercial API ont diminué de 13,4%, tandis que le développement CMC a connu une augmentation de 18,7%. L'entreprise élargit ses capacités de production à l'échelle mondiale, avec des investissements significatifs sur tous les sites. Bachem a commencé à mettre en service des équipements dans sa plus grande usine de production de peptides et d'oligonucléotides à Bubendorf et prévoit un nouveau site de fabrication à Eiken.
Die Bachem-Gruppe (SIX: BANB) vermeldete im ersten Halbjahr 2024 ein leichtes Umsatzwachstum von 0,2% auf 240,3 Millionen CHF, wobei in lokalen Währungen ein Anstieg von 1,3% zu verzeichnen war. Das EBITDA stieg um 5,6% auf 55,5 Millionen CHF bei einer Marge von 23,1%. Das Unternehmen erwartet für 2024 ein Wachstum von mittleren bis hohen einstelligen Prozentzahlen in lokalen Währungen und will eine stabile EBITDA-Marge beibehalten. Bachem strebt an, bis 2026 einen jährlichen Umsatz von über 1 Milliarde CHF und eine EBITDA-Marge von über 30% zu erreichen.
Der Umsatz im Bereich Commercial API fiel um 13,4%, während die CMC-Entwicklung um 18,7% zulegte. Das Unternehmen erweitert weltweit seine Produktionskapazitäten mit erheblichen Investitionen an allen Standorten. Bachem hat mit der Inbetriebnahme von Anlagen in seinem größten Produktionswerk für Peptide und Oligonukleotide in Bubendorf begonnen und plant einen neuen Produktionsstandort in Eiken.
- EBITDA increased by 5.6% to CHF 55.5 million, with margin improvement from 21.9% to 23.1%
- CMC Development sales grew by 18.7% to CHF 90.3 million
- Research & Specialties sales increased by 35.4% to CHF 22.8 million
- Net income rose by 5.0% with a margin improvement from 14.4% to 15.0%
- Significant capacity expansion investments of CHF 143.9 million across all sites
- Commercial API sales declined by 13.4% to CHF 127.2 million
- Overall sales growth was minimal at 0.2% (1.3% in local currencies)
Ad hoc announcement pursuant to Art. 53 LR
| Media Release |
Dear Sir or Madam
Due to server overload our website is currently unavailable, including half year documents.
We are therefore providing you with a separate link for half year information to ensure you have access to all documentation.
Please accept our sincerest apologies for this inconvenience.
Kind Regards
Bachem Group Communications
- Group sales increase slightly to CHF 240.3 million (+
0.2% compared to the prior-year period, +1.3% in local currencies). - EBITDA at CHF 55.5 million (+
5.6% compared to the prior-year period, +8.7% in local currencies) with a margin of23.1% (prior-year period:21.9% ).
Outlook
- For 2024, Bachem expects Group sales to grow in local currencies in the mid- to high-single-digit percentage range.
- The EBITDA margin in lcal currencies should remain stable in 2024 compared to the previous year.
- For 2026, the company aims for annual sales of more than CHF 1 billion and an EBITDA margin of over
30% .
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10552/217634_figure1.jpg
Thomas Meier, CEO of Bachem, on the results for the first half of the year: “At Bachem, we are currently working hard to expand our production capacities worldwide. At the same time, we were able to slightly increase our sales in the first half of the year compared to the previous year. In the second half of the year, we expect a significant increase in sales and profit compared to the first six months, mainly thanks to the good order situation.”
Group Results
Bubendorf, Switzerland--(Newsfile Corp. - July 25, 2024) - The Bachem Group (SIX: BANB) achieved sales of CHF 240.3 million in the first half of 2024 (+
Operating income before depreciation and amortization (EBITDA) amounted to CHF 55.5 million (+
Sales by product categories
The Commercial API category achieved sales of CHF 127.2 million (first half of 2023: CHF 146.9 million, -
In the clinical drug development category (CMC Development), sales increased to CHF 90.3 million (first half of 2023: CHF 76.1 million, +
The research chemicals and specialties business (Research & Specialties) returned to CHF 22.8 million after a strong decline in the prior reporting period (first half of 2023: CHF 16.9 million, +
Capacity expansion
Bachem is implementing an investment program to expand capacity at all sites. In the first half of 2024, CHF 143.9 million were invested across all sites.
Bachem began construction of its largest production plant to date for large volumes of peptides and oligonucleotides in 2021 (building “K”) in Bubendorf. The gradual commissioning of equipment in building “K” has begun. A large portion of building “K” is already booked.
A new manufacturing site is currently planned in Sisslerfeld in the Swiss municipality of Eiken. A third portion of land was purchased in the first half of 2024.
Bachem is also continuing to invest in the infrastructure of the entire network of sites and is focusing even more on site-specific core competencies. In the USA, capacities for high production volumes are being expanded at the Vista site. In Torrance, Bachem is focusing on promising small-volume clinical projects, while investments at the Vionnaz site are aimed at securing the supply of important precursor materials.
The Half-Year Report 2024 and the presentation for the analyst- and media call are available on the website under the following link:
www.bachem.com/about-bachem/investors-and-media/reports-and-presentations
Financial calendar
November 21, 2024, Capital Markets Day
February 27, 2025, Publication Annual Report 2024 / Media- and Analyst Conference
April 30, 2025, Annual General Assembly (financial year 2024)
July 24, 2025, Publication Half Year Report 2025
About Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.
For more information:
Bachem Holding AG
Dr. Daniel Grotzky
Head Group Communications
Tel.: +41 58 595 2021
Media: media@bachem.com
Investors: ir@bachem.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/217634
FAQ
What was Bachem's (BCHMY) sales growth in the first half of 2024?
What is Bachem's (BCHMY) EBITDA margin for the first half of 2024?
What are Bachem's (BCHMY) sales targets for 2026?
How much did Bachem (BCHMY) invest in capacity expansion in the first half of 2024?
